Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

March 2, 2022

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2028

Conditions
Advanced Rectal Cancer
Interventions
DRUG

XELOX

Starting from the first day of radiotherapy (set as day 0), the patient received a total of 4 courses of XELOX chemotherapy on days -42, -21, 42, and 63, including oxaliplatin 130 mg/m2, intravenous administration, d1, repeat every 3 weeks; and capecitabine 1000mg/m2, twice daily, d1-d14, repeat every 3 weeks.

DRUG

Capecitabine monotherapy

During radiotherapy (Monday to Friday), capecitabine was administered at 1650 mg/m2/d, twice a day.

RADIATION

Radiation

The TV is expanded by 6-7mm to form PTV1, and the CTV is expanded by 6-7mm to form PTV2. The dose of PTV1 was 50Gy/25 times/35 days, and the dose of PTV2 was 45Gy/25 times/35 days, 5 times/week for a total of 5 weeks.

Trial Locations (1)

Unknown

RECRUITING

Zhenhai Lu, Guangzhou

All Listed Sponsors
lead

Zhen-Hai Lu

OTHER